Evaluation of the effects of photodynamic therapy with phosphorus 31 magnetic resonance spectroscopy.
Magnetic resonance spectroscopy in situ was used to study changes in phosphorus 31 metabolism after photodynamic therapy (PDT) of transplanted HeLa cell tumours. Tumours were irradiated 2 h after administration of ATX-S10 (8-formyloximethylidene-7-hydroxy-3-ethenyl-2,7,12,18, tetramethyl-porphyrin-13,17-bispropionil aspartate), a new photosensitizer and chlorin derivative. Nuclear magnetic resonance spectra were measured prior to illumination and 1, 3, 7, 14, 21 and 28 days after PDT on each mouse. A drastic decrease in adenosine triphosphate (ATP) and a concomitant increase in inorganic phosphate (Pi) were evident on the first day after PDT in all cases. The beta-ATP/total phosphate (P) ratio was 0.64 +/- 0.29% (average +/- s.d.) in complete response, 0.67 +/- 0.30% in recurrence and 2.45 +/- 0.93% in partial response. Comparison of this ratio to the histological findings revealed that the beta-ATP/total P ratio reflects the HeLa cell tumours which survived PDT. In other words, partial response on the one hand was distinguished from complete response and recurrence on the other with this ratio 1 day after PDT (P < 0.05). In addition, the ratio of phosphomonoester (PME) to Pi rose beyond 1.0 when macroscopic recurrence occurred, while it stayed under 1.0 in complete response. This finding suggests that the recurrence of HeLa cell tumours can be detected by the PME/Pi ratio.
Nishiwaki
M
M
Department of Microbiology and Immunology, Hamamatsu University School of Medicine, Handa-cho Hamamatsu, Japan.
Fujise
Y
Y
Yoshida
T O
TO
Matsuzawa
E
E
Nishiwaki
Y
Y
D000255:Adenosine Triphosphate / Q000378:metabolism*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D005260:Female; D006367:HeLa Cells; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D010710:Phosphates / Q000378:metabolism; D010758:Phosphorus / Q000378:metabolism*; D010759:Phosphorus Isotopes; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000494:pharmacology*; D011166:Porphyrins / Q000494:pharmacology*
C117772:ATX S10Na(II); D000970:Antineoplastic Agents; D010710:Phosphates; D010759:Phosphorus Isotopes; D017319:Photosensitizing Agents; D011166:Porphyrins; D010758:Phosphorus; D000255:Adenosine Triphosphate